- Trials with a EudraCT protocol (2,061)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (1)
2,061 result(s) found for: Drug clearance.
Displaying page 5 of 104.
EudraCT Number: 2006-002403-13 | Sponsor Protocol Number: Ularitide-1502 | Start Date*: 2006-11-20 | |||||||||||
Sponsor Name:PDL BioPharma Inc | |||||||||||||
Full Title: A Phase 3, Randomized, Double-blinded, Placebo-controlled Study of Ularitide in the Treatment of Subjects with Acute Decompensated Heart Failure | |||||||||||||
Medical condition: Acute decompensated heart failure | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Prematurely Ended) LT (Prematurely Ended) AT (Temporarily Halted) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-002468-24 | Sponsor Protocol Number: NV20234 | Start Date*: 2008-02-13 | |||||||||||
Sponsor Name:F.Hoffmann-La Roche Ltd. | |||||||||||||
Full Title: A double-blind, randomized, stratified, multi-center trial evaluating conventional and high dose oseltamivir in the treatment of immunocompromised patients with influenza | |||||||||||||
Medical condition: To investigate the optimal therapy for influenza in immunocompromised transplant recipients. | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) ES (Completed) FR (Completed) BE (Completed) HU (Completed) LT (Completed) CZ (Completed) EE (Completed) IT (Completed) GR (Prematurely Ended) BG (Completed) LV (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-004382-83 | Sponsor Protocol Number: ALA-AK-CT009 | Start Date*: 2016-06-09 | |||||||||||
Sponsor Name:Biofrontera Bioscience GmbH | |||||||||||||
Full Title: A randomized, observer-blind, intra-individual phase III study to evaluate the safety and efficacy of BF 200 ALA (Ameluz®) in combination with daylight-PDT (photodynamic therapy) in comparison with... | |||||||||||||
Medical condition: Actinic keratosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-004049-29 | Sponsor Protocol Number: ISSBRIL0264 | Start Date*: 2015-03-10 |
Sponsor Name:University of Leicester | ||
Full Title: Investigating Aspirin and Ticagrelor for the prevention of tumour cell-induced platelet aggregation | ||
Medical condition: Solid cancer metastasis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2015-001172-21 | Sponsor Protocol Number: CLO05908 | Start Date*: 2015-05-18 | |||||||||||
Sponsor Name:Genzyme Japan K.K. | |||||||||||||
Full Title: A Phase 1, Open-label, Multi-center Study of Clofarabine in Japanese Pediatric Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia | |||||||||||||
Medical condition: Acute Lymphoblastic Leukemia | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-001125-13 | Sponsor Protocol Number: SAHIV-IMEA50 | Start Date*: 2017-04-07 | |||||||||||
Sponsor Name:IMEA (Institut de Médecine et d’Epidémiologie Appliquée)–Fondation Léon M’Ba | |||||||||||||
Full Title: Pilot study - Short duration therapy of acute hepatitis C genotypes 1 or 4 in HIV-infected patients: efficacy and tolerability of grazoprevir 100mg/elbasvir 50mg during 8 weeks | |||||||||||||
Medical condition: Acute hepatitis C (genotypes 1 or 4) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-005532-29 | Sponsor Protocol Number: A0001B | Start Date*: 2021-04-27 | |||||||||||||||||||||
Sponsor Name:Toscana Life Sciences Sviluppo | |||||||||||||||||||||||
Full Title: Randomized, placebo-controlled, double-blind, multicenter, seamless adaptive phase II-III clinical trial to select the dose and evaluate safety and efficacy of MAD0004J08 monoclonal antibody in adu... | |||||||||||||||||||||||
Medical condition: SARS-CoV2 treatment. | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: IT (Completed) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-004013-16 | Sponsor Protocol Number: D3720C00001 | Start Date*: 2012-03-08 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A Phase III, Multicentre, Randomised, Double-Blind, Comparative Study to Evaluate the Efficacy and Safety of Ceftaroline Fosamil (600mg every 8 hours) Versus Vancomycin Plus Aztreonam in the Treatm... | |||||||||||||
Medical condition: Complicated bacterial skin and soft tissue infections | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GR (Completed) BE (Completed) CZ (Completed) BG (Completed) DE (Completed) AT (Completed) PL (Completed) ES (Completed) GB (Completed) SK (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-003900-30 | Sponsor Protocol Number: M16-043 | Start Date*: 2017-06-28 | |||||||||||
Sponsor Name:AbbVie Deutschland GmbH & Co. KG | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo Controlled Phase 3 Study of Venetoclax Co-Administered with Low Dose Cytarabine Versus Low Dose Cytarabine in Treatment Naïve Patients with Acute Myeloid Leukemi... | |||||||||||||
Medical condition: Acute Myeloid Leukemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) IE (Prematurely Ended) DE (Completed) NO (Completed) GR (Completed) HU (Completed) BE (Completed) ES (Ongoing) GB (GB - no longer in EU/EEA) FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-005496-17 | Sponsor Protocol Number: C16010 | Start Date*: 2012-10-10 | |||||||||||
Sponsor Name:Millennium Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Phase 3, Randomized, Double-Blind, Multicenter Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed ... | |||||||||||||
Medical condition: Relapsed and/or Refractory Multiple Myeloma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) BE (Completed) GB (GB - no longer in EU/EEA) HU (Completed) PT (Completed) AT (Completed) ES (Restarted) CZ (Completed) SE (Completed) IT (Completed) FR (Completed) NL (Completed) DK (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-014762-26 | Sponsor Protocol Number: RDEA594-204 | Start Date*: 2009-10-27 | |||||||||||
Sponsor Name:Ardea Biosciences, Inc. | |||||||||||||
Full Title: A Phase 2, Multiple-Dose, Pharmacokinetic and Pharmacodynamic Study of RDEA594 in Gout Patients with Hyperuricemia and Gout with Renal Insufficiency | |||||||||||||
Medical condition: Gout. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-003826-10 | Sponsor Protocol Number: EAGLE | Start Date*: 2014-01-24 |
Sponsor Name:IRCCS- Mario Negri Institute | ||
Full Title: EVALUATING THE MORPHOFUNCTIONAL EFFECTS OF ECULIZUMAB THERAPY IN PRIMARY MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS: A PILOT, SINGLE ARM STUDY IN TEN PATIENTS WITH PERSISTENT HEAVY PROTEINURIA | ||
Medical condition: Membranoproliferative glomerulonephritis | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2014-004958-34 | Sponsor Protocol Number: UNOLE0457 | Start Date*: 2015-01-30 |
Sponsor Name:University of Leicester | ||
Full Title: Midazolam Measurement and Modelling using Matrix Samplers | ||
Medical condition: Not applicable | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2013-002255-15 | Sponsor Protocol Number: ST3073-ST3074-DM-12-002 | Start Date*: 2014-11-04 |
Sponsor Name:Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. | ||
Full Title: A phase II, open-label, multicentre, pharmacokinetic, pharmacodynamics and safety study of a new paediatric eurartesim dispersible formulation and crushed film coated eurartesim tablet, in infant p... | ||
Medical condition: Uncomplicated Plasmodium falciparum malaria | ||
Disease: | ||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2016-001143-40 | Sponsor Protocol Number: OBEMO1EXT | Start Date*: 2016-06-22 |
Sponsor Name:Therapeutic Research Unit | ||
Full Title: Long-term effects of Roux-en-Y Gastric Bypass on morphine exposure after oral administration of immediate release morphine, in comparison with subjects without surgery | ||
Medical condition: Subjects volunteers who undergone Roux-en-Y gastric bypass (RYGB) for at least 48 months and control subjects matched for BMI, age and sex | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2005-000127-42 | Sponsor Protocol Number: NRSily1 | Start Date*: 2005-03-03 |
Sponsor Name:Medical University of Vienna | ||
Full Title: Non Responder- STUDY: MULTICENTER STUDY TO EVALUATE THE EFFICACY OF SILYMARIN IN ADDITION TO COMBINATION-THERAPY WITH PEGYLATED INTERFERON ALFA 2A (PEG-IFN ALFA 2A) AND RIBAVIRIN IN PATIENTS WI... | ||
Medical condition: HCV-patients, who have not responded to a previous therapy with INF or PEG-INF +/- Ribavirin. | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2005-005987-94 | Sponsor Protocol Number: GAHB-Study | Start Date*: 2006-07-17 | |||||||||||
Sponsor Name:University of Leipzig | |||||||||||||
Full Title: Double-blind placebo-controlled randomised trial of lamivudine in the treatment of acute hepatitis B | |||||||||||||
Medical condition: Acute Hepatitis B | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-002077-31 | Sponsor Protocol Number: RIMON_L_01814 | Start Date*: 2008-09-09 | |||||||||||
Sponsor Name:SANOFI-AVENTIS S.P.A | |||||||||||||
Full Title: Effects of Rimonabant on urinary albumin excretion rate on the components of the metabolic syndrome in patients with type 2 diabetes mellitus and microalbuminuria on background ramipril treatment. ... | |||||||||||||
Medical condition: Abdominal obese patients with type 2 diabetes mellitus and microalbuminuria. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-002996-27 | Sponsor Protocol Number: 13CC34 | Start Date*: 2015-02-02 |
Sponsor Name:Great Ormond Street Hospital For Children NHS Foundation Trust | ||
Full Title: Optimising effectiveness and minimising toxicity of intravenous salbutamol in children with acute asthma | ||
Medical condition: The mainstay of asthma treatment worldwide are β2-agonists and steroids. Current management of childhood acute asthma is based on British Thoracic Society guidelines, which recommend IVS as second ... | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: GB (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2006-001836-32 | Sponsor Protocol Number: H3E-IT-S105 | Start Date*: 2006-08-01 | |||||||||||
Sponsor Name:ELI LILLY | |||||||||||||
Full Title: Pemetrexed monochemotherapy in patients with locally advanced or metastatic Non Small Cell Lung Cancer. A pilot study to define the best dosing schedule for a planned phase II randomized trial. | |||||||||||||
Medical condition: IIIB and IV non-small cell lung cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
